Internal Medicine
| 2 min read
To boost opportunities in the industrial fermentation market, including pharmaceuticals, the Netherlands’ Kluyver Centre—a joint industry and academic consortium that applies genomics to improve industrial fermentation—has turned to Swiss bioinformatics company Genedata.
| 2 min read
Eksigent and Phenomenex Inc. have embarked on a strategic marketing and technology collaboration to develop columns optimized for capillary HPLC systems.
| 2 min read
VisualSonics announced an exclusive agreement with the Bracco Group for the joint development and manufacture of a new line of MicroMarker contrast agents for use in preclinical molecular imaging on the VisualSonics Vevo 770 micro-ultrasound platform.
| 2 min read
In a recent issue of Science, researchers from The Institute for Genomic Research (TIGR) and colleagues examined the biological universe of the human colon and found more than 1,000 microbial species.
| 2 min read
Biogen Idec and Fumapharm AG, a privately held pharmaceutical company, in late spring announced a definitive agreement whereby Fumapharm will be acquired by Biogen Idec.
| 2 min read
Generex Biotechnology and Fertin Pharma A/S recently announced a collaboration for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity.
| 3 min read
Early last month, when Thermo Electron and Fisher Scientific executives convened the conference call to announce what to date is the largest merger of its kind in the life sciences industry, one phrase kept popping up during the call: “industry transforming transaction.”
| 4 min read
Every major pharmaceutical company has by now invested in supercritical or sub-critical fluid chromatography (SFC) technology. This fact represents a win-win situation. Scientists like SFC because it is greener, safer, cleaner, and uses more nearly inert and easier to recycle solvents in the research laboratory compared to LC.
| 3 min read
The most popular tool for modulating gene activity is RNAi knockdown, but the logical alternative, cDNA overexpression, has also proven fruitful in discovering new gene functions. Why, then, has it gotten so little attention compared to RNAi? Let’s see how these two alternatives actually compare.
| 1 min read
Most current DNA-based technologies are intrinsically high-throughput
| 2 min read
Seeking to help distinguish its immunotoxicity competencies from the phage-based biosensor business that is its namesake, Biophage Pharma Inc. recently completed a restructuring of its contract research organization (CRO) business.
